Boon Hao Hong

Boon Hao Hong

Auto-generated profile, based on publicly available information

Boon Hao Hong

National Cancer Centre Singapore 1 , Singapore, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2021 in Acta Informatica Pragensia
Verified
Journal Article
Open access
PDF file
BHBoon Hao Hong
Boon Hao Hong
Jane LabadinJane Labadin
Jane Labadin
WTWei King Tiong
Wei King Tiong
TLTerrin Lim
Terrin Lim
MLMelvin Chung Hsien Liang
Melvin Chung Hsien Liang
Peer-reviewed journal on social and business aspects of informatics that covers the theory and application of enterprise information systems, as well as interactions between ICT and people. Recenzovan? ?asopis o soci?ln?ch a byznys aspektech informatiky zahrnuj?c? teorie a aplikace podnikov?ch informa?n?ch syst?m? a interakce mezi ICT a lidmi.

2 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
AKAnson T. Ku
Anson T. Ku
USUma Shankavaram
Uma Shankavaram
STShana Y. Trostel
Shana Y. Trostel
HZHong Zhang
Hong Zhang
SKSumeyra Kartal
Sumeyra Kartal
DCDeborah E. Citrin
Deborah E. Citrin
Purpose: Clinical risk grouping based on PSA, tumor grade, and disease extent guides treatment intensity for localized prostate cancer. However, many patients with intermediate- or high-risk disease treated with external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) still develop biochemical recurrence (BCR). Early identification of patients at high risk for BCR could enable personalized treatment strategies. Experimental Design: We prospectively enrolled 29 patients with intermediate- or high-risk prostate cancer undergoing EBRT and ADT. Pretreatment biopsies (n = 60) underwent whole-transcriptome microarray and whole-exome sequencing. Patients received multiparametric MRI at baseline and 6 months after treatment, with a median follow-up of 6 years. Gene expression differences between patients with and without BCR were analyzed using pathway tools and validated in external datasets. A novel TGF-β gene signature was derived and tested across multiple cohorts (median follow-up: 5–11 years). Results: TGF-β activity was significantly associated with BCR in the discovery cohort (P = 0.0081) and correlated with PTEN/TP53 alterations (P = 0.0246) and baseline multiparametric MRI tumor volume (P = 0.026). TGF-β activity also predicted metastasis-free survival (P = 0.037) and, in an independent cohort (n = 265), was prognostic for BCR-free (P = 0.05), metastasis-free (P < 0.001), and overall survival (P < 0.001). Conclusions: TGF-β activity is a dominant feature of intermediate- to unfavorable-risk prostate tumors prone to biochemical failure after EBRT with ADT and may serve as an independent prognostic biomarker beyond existing clinical criteria.

1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RHRoni Haas
Roni Haas
GFGavin Frame
Gavin Frame
SKShahbaz Khan
Shahbaz Khan
Beth NeilsenBeth Neilsen
Beth Neilsen
BHBoon Hao Hong
Boon Hao Hong
SLStanley K Liu
Stanley K Liu
Prostate cancer is frequently treated with radiotherapy. Unfortunately, aggressive radioresistant relapses can arise, and the molecular underpinnings of radioresistance are unknown. Modern clinical radiotherapy is evolving to deliver higher doses of radiation in fewer fractions (hypofractionation). We therefore analyzed genomic, transcriptomic, and proteomic data to characterize prostate cancer radioresistance in cells treated with both conventionally fractionated and hypofractionated radiotherapy. Independent of fractionation schedule, resistance to radiotherapy involved massive genomic instability and abrogation of DNA mismatch repair. Specific prostate cancer driver genes were modulated at the RNA and protein levels, with distinct protein subcellular responses to radiotherapy. Conventional fractionation led to a far more aggressive biomolecular response than hypofractionation. Testing preclinical candidates identified in cell lines, we revealed POLQ (DNA Polymerase Theta) as a radiosensitizer. POLQ-modulated radioresistance in model systems and was predictive of it in large patient cohorts. The molecular response to radiation is highly multimodal and sheds light on prostate cancer lethality. Significance: Radiation is standard of care in prostate cancer. Yet, we have little understanding of its failure. We demonstrate a new paradigm that radioresistance is fractionation specific and identified POLQ as a radioresistance modulator.

28 May 2025 in Journal of the National Cancer Center
Verified
Journal Article
Open access
KTKae Jack Tay
Kae Jack Tay
BHBoon Hao Hong
Boon Hao Hong
EOEnya Hui Wen Ong
Enya Hui Wen Ong
KTKah Min Tan
Kah Min Tan
GPGianella Cabuhat Pacho
Gianella Cabuhat Pacho
MCMelvin Lee Kiang Chua
Melvin Lee Kiang Chua
Focal therapy (FT) is a potential treatment option for limited-volume clinically-significant prostate cancer (csPCa). However, despite rigorous selection, approximately 20% of patients experience early failure. We investigated the association of transcriptomic profiles and csPCa recurrence post-FT. 52 men from a phase II trial (NCT04138914) and a prospective observational cohort underwent focal cryotherapy for csPCa. Patients underwent multiparametric magnetic resonance imaging, and targeted and systematic-saturation biopsy before- and 1-year post-FT. Recurrence was defined as grade-group (GG) ≥2 cancer in the 1-year post-FT biopsy. Pre-treatment lesions were profiled using the Decipher genomic classifier (GC). GC scores, luminal-basal status, tumor microenvironment and cancer hallmark pathways were correlated with csPCa recurrence. Median PSA was 7.0 ng/dl; 37/52 (71.1%) men had GG2, 12/52 (23.1%) GG3, and 3/52 (5.8%) GG4 cancer. Recurrence was observed in 9/52 (17.3%) men. Median GC score was higher in patients with recurrence (0.60 vs 0.38, P = 0.014) and remained significantly associated with recurrence after adjustment for GG (adjusted OR: 1.37 [95% CI: 1.01-1.93], P = 0.04). Luminal-proliferative tumors based on the prostate cancer-specific subtyping classifier (PSC) had more csPCa recurrence compared with luminal-differentiated (LD) and basal subtypes (30.4% vs 0% [LD] vs 15.4% [basal-neuroendocrine] and 14.3% [basal-immune], P = 0.027). Higher expression of DNA repair pathway was also associated with recurrence (OR: 2.12 [95% CI: 1.09-4.57], P = 0.025). Higher GC score is associated with risk of csPCa recurrence post-FT. Patients with GC low-risk and PSC-LD csPCa may represent the ideal subgroup for FT. Prospective validation in a large cohort is warranted.

24 December 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CBChaw Yee Beh
Chaw Yee Beh
CYCelestia Pei Xuan Yeo
Celestia Pei Xuan Yeo
BHBoon Hao Hong
Boon Hao Hong
ETEvelyn Mui Cheng Tan
Evelyn Mui Cheng Tan
KTKah Min Tan
Kah Min Tan
MCMelvin LK Chua
Melvin LK Chua
Radiotherapy is an integral modality in treating human cancers, but radioresistance remains a clinical challenge due to the involvement of multiple intrinsic cellular and extrinsic tumour microenvironment factors that govern radiosensitivity. To study the intrinsic factors that are associated with cancer radioresistance, we established 4 radioresistant prostate (22Rv1 and DU145) and head and neck cancer (FaDu and HK1) models by irradiating their wild-type parentals to 90 Gy, mimicking the fractionated radiotherapy schema that is often using in the clinic, and performed whole exome and transcriptome sequencing of the radioresistant and wild-type models. Comparative genomic analyses detected the enrichment of mismatch repair mutational signatures (SBS6, 14, 15, 20) across all the cell lines and several non-synonymous single nucleotide variants involved in pro-survival pathways. Despite significant inter-cell type heterogeneity of their transcriptomic profiles, 18 common dysregulated genes (5 upregulated and 13 downregulated) were identified across the 4 models, including the overexpression of bromo-adjacent homology domain containing 1 (BAHD1) gene, which is involved in heterochromatin formation. Interestingly, this coincided with our observation of increased histone 3 lysine 9 trimethylation (H3K9me3) and histone 3 lysine 27 trimethylation (H3K27me3) expression post-irradiation in our radioresistant cells. The dependency between BAHD1 and heterochromatin formation was confirmed by siRNA knockdown of BAHD1, indicating preferential reduction of H3K9me3 and H3K27me3 expression in the radioresistant cells, but not the wild-type parentals, and confirmed by clonogenic assays showing reversal of radioresistance post-siBAHD1 treatment. We further showed that inhibition of the BAHD1-heterochromatin formation axis led to reduced DNA double-strand break repair. Finally, analyses of treatment outcomes in 4 prostate and head and neck cancer radiotherapy cohorts suggested an increased risk of failures in tumours of high heterochromatin activity. Taken together, our results support a new model implicating BAHD1-dependent modulation of the heterochromatin in acquired radioresistance of prostate and head and neck cancers.

17 June 2026
Verified
Other
Open access
PDF file
RHRoni Haas
Roni Haas
GFGavin Frame
Gavin Frame
SKShahbaz Khan
Shahbaz Khan
Beth NeilsenBeth Neilsen
Beth Neilsen
BHBoon Hao Hong
Boon Hao Hong
SLStanley K Liu
Stanley K Liu